摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(苄氧基)-4-溴吡啶 | 960298-00-4

中文名称
2-(苄氧基)-4-溴吡啶
中文别名
——
英文名称
2-(benzyloxy)-4-bromopyridine
英文别名
4-bromo-2-phenylmethoxypyridine
2-(苄氧基)-4-溴吡啶化学式
CAS
960298-00-4
化学式
C12H10BrNO
mdl
——
分子量
264.121
InChiKey
ZBTZIRNIUHLSSJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    22.1
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    2-8°C

SDS

SDS:e31ace5a5b9c90d3e9bafcf2618005c9
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-(Benzyloxy)-4-bromopyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Benzyloxy)-4-bromopyridine
CAS number: 960298-00-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H10BrNO
Molecular weight: 264.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(苄氧基)-4-溴吡啶盐酸 作用下, 以 甲醇 为溶剂, 以82%的产率得到4-溴-2-羟基吡啶
    参考文献:
    名称:
    4-Halo-2-pyridones 和 3-Bromo-4-halo-2-pyridones 的简明条目
    摘要:
    描述了合成简单的 4-卤-2-吡啶酮和更多官能化的 3,4-二-和(3,4,5-三)-卤-2-吡啶酮的方法,这些方法基于 Sandmeyer 和区域选择性(铜介导的)卤化,用 2-氯或 2-苄氧基部分作为掩蔽的 2-吡啶酮。
    DOI:
    10.1055/s-0035-1560469
  • 作为产物:
    描述:
    2-氯-4-氨基吡啶亚硝酸特丁酯 、 potassium hydroxide 、 copper(ll) bromide 作用下, 以 甲苯乙腈 为溶剂, 反应 16.0h, 生成 2-(苄氧基)-4-溴吡啶
    参考文献:
    名称:
    4-Halo-2-pyridones 和 3-Bromo-4-halo-2-pyridones 的简明条目
    摘要:
    描述了合成简单的 4-卤-2-吡啶酮和更多官能化的 3,4-二-和(3,4,5-三)-卤-2-吡啶酮的方法,这些方法基于 Sandmeyer 和区域选择性(铜介导的)卤化,用 2-氯或 2-苄氧基部分作为掩蔽的 2-吡啶酮。
    DOI:
    10.1055/s-0035-1560469
点击查看最新优质反应信息

文献信息

  • [EN] THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS<br/>[FR] THIÉNO[3,2-C]PYRIDIN-4(5H)-ONES UTILES COMME INHIBITEURS DE BET
    申请人:GLAXOSMITHKLINE LLC
    公开号:WO2014078257A1
    公开(公告)日:2014-05-22
    Thienopyridone compounds of formula (I) or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
    噻诺吡啶酮化合物或其盐,含有该化合物的药物组合物及其在治疗中的用途,特别是在溴结构域抑制剂用于治疗的疾病或症状中。
  • Copper-Mediated Perfluoroalkylation of Heteroaryl Bromides with (phen)CuR<sub>F</sub>
    作者:Michael G. Mormino、Patrick S. Fier、John F. Hartwig
    DOI:10.1021/ol500422t
    日期:2014.3.21
    synthetic goal over the past several decades. Previously, our group reported phenanthroline-ligated perfluoroalkyl copper reagents, (phen)CuRF, which react with aryl iodides and aryl boronates to form the corresponding benzotrifluorides. Herein the perfluoroalkylation of a series of heteroaryl bromides with (phen)CuCF3 and (phen)CuCF2CF3 is reported. The mild reaction conditions allow the process to tolerate
    在过去的几十年里,将全氟烷基连接到有机化合物上一直是一个主要的合成目标。以前,我们的小组报道了菲咯啉连接的全氟烷基铜试剂 (phen)CuR F,它与芳基碘化物和芳基硼​​酸酯反应形成相应的三氟化苯。本文报道了一系列杂芳基溴化物与 (phen)CuCF 3和 (phen)CuCF 2 CF 3的全氟烷基化。温和的反应条件允许该过程耐受许多常见的官能团。使用 (phen)CuCF 2 CF 3 进行全氟乙基化的产率比使用 (phen)CuCF 3 进行三氟甲基化的产率略高,创建了一种生成氟代烷基杂芳烃的方法,这些杂芳烃不易从三氟乙酸衍生物中获得。
  • [EN] RENIN INHIBITORS<br/>[FR] INHIBITEURS DE LA RÉNINE
    申请人:MERCK FROSST CANADA LTD
    公开号:WO2009070869A1
    公开(公告)日:2009-06-11
    The present invention relates to piperidinyl-based renin inhibitor compounds having the formula containing amino-terminal groups, and their use in treating cardiovascular events and renal insufficiency.
    本发明涉及含有氨基末端基团的哌啶基肾素抑制剂化合物,以及它们在治疗心血管事件和肾功能不全方面的用途。
  • [EN] 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE SUBSTITUÉS EN 3,4 UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉNINE
    申请人:MERCK FROSST CANADA LTD
    公开号:WO2009135299A1
    公开(公告)日:2009-11-12
    The present invention relates to 3,4-substituted piperidinyl-based renin inhibitor compounds bearing at 4-position oxopyridine and having the formula (I). The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.
    本发明涉及具有在4位氧吡啶基的3,4-取代哌啶基肾素抑制剂化合物,其化学式为(I)。该发明还涉及含有上述化合物的药物组合物,以及它们在治疗心血管事件和肾功能不全中的用途。
  • [EN] GPR40 AGONISTS<br/>[FR] AGONISTES DE GPR40
    申请人:KALLYOPE INC
    公开号:WO2021174048A1
    公开(公告)日:2021-09-02
    This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    这项披露至少部分涉及对GPR40激动剂的研究,用于治疗涉及肠脑轴的疾病或疾病。在某些实施例中,GPR40激动剂是肠道限制性化合物。在某些实施例中,GPR40激动剂是全激动剂或部分激动剂。在某些实施例中,该疾病或疾病是代谢性疾病,如糖尿病、肥胖症、非酒精性脂肪肝炎(NASH)或营养紊乱,如短肠综合征。
查看更多